

PUBLICATIONS GAVIN MARX

Tan A, **Marx G**. Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia. *BMJ Case Reports* 2018; doi: 10.1136/bcr-2017-22294

Tan AC, Li BT, Nahar K, Danieletto S, Fong ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, Rutovitz JJ, McCloud P, Hughes TM, **Marx GM**. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early oestrogen receptor-positive breast cancer. *Asia Pacific Journal of Clinical Oncology* 2018 Apr 14 (2):e161-e166. doi: 10.1111/ajco.12779. Epub 2017 Sep 29

Nahm N, Mee S, **Marx G**. Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. *Asia Pacific Journal of Clinical Oncology* 2018; 1–9

JN Pulvers, **G Marx**. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. *Asia Pacific Journal of Clinical Oncology*, 2017

Hui-Ming Lin^{1,2}, Kate L Mahon^{1,2,3,4}, Calan Spielman¹, Howard Gurney^{5,6}, Girish Mallesara^{6,7}, Martin R Stockler^{3,4,6,8,9}, Patricia Bastick^{6,10}, Karen Briscoe^{6,11}, **Gavin Marx**^{6,12}, Alexander Swarbrick^{1,2} and Lisa G Horvath. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. *British Journal of Cancer* (2017) 116, 1002–1011
doi:10.1038/bjc.2017.50 www.bjcancer.com March 2017

Thomas CL^{1,2}, Arasaratnam M³, Carlos G^{1,2,4}, Parasyn A⁵, Baumgart KW⁶, Fernandez-Penas P^{1,2,4}, **Marx G**^{2,3}. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. *Australas J Dermatol*. 2017 Feb; 58(1):69-70

Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, Piyushkumar A Mundra, Calan Spielman, Karen Briscoe, Howard Gurney, Girish Mallesara, **Gavin Marx**, Martin R Stockler, Robert G Parton, Andrew J Hoy, Roger J Daly, Peter J Meikle, Lisa G Horvath. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. *Int Journal of Cancer* Aug 2017

J N Pulvers, **G Marx**. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. *Asia-Pacific Journal of Clinical Oncology*, 2017

Hui-Ming Lin 1,2, Kate L Mahon 1,2,3,4, Calan Spielman 1, Howard Gurney 5,6, Girish Mallesara 6,7, Martin R Stockler 3,4,6,8,9, Patricia Bastick 6,10, Karen Briscoe 6,11, **Gavin Marx 6,12**, Alexander Swarbrick 1,2 and Lisa G Horvath. Phase 2 study of circulating microRNA biomarkers in castration-

resistant prostate cancer. *British Journal of Cancer* (2017) 116, 1002–1011. doi:10.1038/bjc.2017.50 www.bjcancer.com March 2017

Thomas CL^{1,2}, Arasaratnam M³, Carlos G^{1,2,4}, Parasyn A⁵, Baumgart KW⁶, Fernandez-Penas P^{1,2,4}, **Marx G**^{2,3}. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. *Australas J Dermatol*. 2017 Feb; 58(1):69-70

A. R. T. Bergin, E. Hovey, A. Lloyd, **G. Marx**, P. Parente, T. Rapke, P. de Souza. Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. *Support Care Cancer* September 2017

Bergin A, Hovey E, Lloyd A, **Marx G**, Parente P, Rapke T, De Souza P. Docetaxel-related Fatigue in Metastatic Prostate Cancer: A Descriptive Analysis. *Asia-Pacific Journal of Clinical Oncology* 12:52-52 August 2016

Li B, Barnes T, Chan D, Naidoo J, Lee A, Khasraw M, **Marx G**, Kris M, Clarke S, Drilon A, Pavlakis N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small cell lung cancers: A meta-analysis of randomized trials. *Lung Cancer*, 102, 21-27 2016

Roger von Moos, Jean Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Lesley Fallowfield, Donald L. Patrick, Charles Cleeland, Danail Damyanov, Felipe Salvador Palazzo, **Gavin Marx**, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. *Supportive Care in Cancer*. March 2016

Kao S, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, **Marx G**, Cullen M, Kerestes Z, Pavlakis N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. *Lung cancer (Amsterdam, Netherlands)*. 75(2), 248-54. 2012

Tebbutt N, Murphy F, Zannino D, Wilson K, Cummins M, Abdi E, Strickland A, Lowenthal R, **Marx G**, Karapetis C, Shannon J, Goldstein D, Nayagam S, Blum R, Chantrill L, Simes R, Price T, Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. *Annals of Oncology* 2011

Christos S Karapetis, Kerry A Cheong, Desmond Yip, Andrew H Strickland, Christopher Steer, **Gavin Marx**, Sonia Yip, Kathryn Chrystal, Peter G Harper. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced oesophagogastric carcinomas. *Asia-*

Pacific Journal of Clinical Oncology. [Volume 6, Issue 4](#), pages 298–305, December 2010

Diana Adams and **Gavin Marx**. Daily Life As An Australian Medical Oncologist. *Journal of Oncology Practice*, Vol 6, No 3 (May), 2010: pp. 146-148

C B Steer, **G M Marx**, N Singhal, M McJannett, D Goldstein, R Prowse. Cancer in older people: a tale of two disciplines *Internal Medicine Journal*. Volume 39, Issue 11, Date: November 2009, 39(11) Pages: 771-775

M Khasraw¹, N Pavlakis¹, S McCowatt^{1,2}, C Underhill³, S Begbie⁴, P de Souza⁵, A Boyce⁶, F Parnis⁷, V Lim¹, R Harvie¹, and **G Marx**. Multicentre Phase I/II Study of PI-88, a Heparanase Inhibitor in Combination with Docetaxel in Patients with Metastatic Castrate- Resistant Prostate Cancer. *Annals of Oncology*, November 2009

Liangli Zhao¹, Brian Y Lee¹, David A Brown³, Mark P Molloy⁴, **Gavin M Marx**⁵, Nick Pavlakis⁵, Michael J Boyer⁶, Martin R Stockler⁶, Warren Kaplan², Samuel N Breit³, Robert L Sutherland¹, Susan M Henshall¹ and Lisa G Horvath Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. *Cancer Research* 69, 7696, October 1, 2009

Pavlakis N, **Marx G**, White S, Lee CW, Khasraw M. Anti-angiogenic therapy for lung cancer (Protocol). *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD008047. DOI: 10.1002/14651858.CD008047

Elizabeth Hovey¹, **Gavin Marx**², Andrew Kneebone³, Manish Patel⁴ and Jeremy Shapiro An Australian Clinical Perspective: Management of Hormone Refractory (Androgen-Independent) Prostate Cancer. *Asia Pacific Journal of Oncology and Haematology* 2009